GHRS Stock Overview
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GH Research PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.72 |
| 52 Week High | US$14.64 |
| 52 Week Low | US$5.05 |
| Beta | 0.84 |
| 1 Month Change | 8.82% |
| 3 Month Change | 86.03% |
| 1 Year Change | 48.35% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.12% |
Recent News & Updates
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Mar 01
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Nov 17GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Jul 30Recent updates
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Mar 01GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Nov 17GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Jul 30We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely
Mar 13Companies Like GH Research (NASDAQ:GHRS) Are In A Position To Invest In Growth
Nov 28GH Research GAAP EPS of $0.006
Aug 23We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth
Aug 15GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Apr 29We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate
Jan 13GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Sep 30GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot Industry
Aug 15Shareholder Returns
| GHRS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.6% | -1.5% | -3.2% |
| 1Y | 48.4% | 9.7% | 19.3% |
Return vs Industry: GHRS exceeded the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: GHRS exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| GHRS volatility | |
|---|---|
| GHRS Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GHRS's share price has been volatile over the past 3 months.
Volatility Over Time: GHRS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 49 | Theis Terwey | www.ghres.com |
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company’s lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression.
GH Research PLC Fundamentals Summary
| GHRS fundamental statistics | |
|---|---|
| Market cap | US$609.77m |
| Earnings (TTM) | -US$35.59m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-17.1x
P/E RatioIs GHRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GHRS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$35.59m |
| Earnings | -US$35.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GHRS perform over the long term?
See historical performance and comparison